DK1800134T3 - Fremgangsmåde til diagnosticering og behandling af Chron's sygdom - Google Patents

Fremgangsmåde til diagnosticering og behandling af Chron's sygdom

Info

Publication number
DK1800134T3
DK1800134T3 DK05809109T DK05809109T DK1800134T3 DK 1800134 T3 DK1800134 T3 DK 1800134T3 DK 05809109 T DK05809109 T DK 05809109T DK 05809109 T DK05809109 T DK 05809109T DK 1800134 T3 DK1800134 T3 DK 1800134T3
Authority
DK
Denmark
Prior art keywords
disease
diagnosing
chron
treating
crohn
Prior art date
Application number
DK05809109T
Other languages
Danish (da)
English (en)
Inventor
Nicolas Barnich
Arlette Darfeuille-Michaud
Anne-Lise Glasser
Original Assignee
Univ Clermont Auvergne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Clermont Auvergne filed Critical Univ Clermont Auvergne
Application granted granted Critical
Publication of DK1800134T3 publication Critical patent/DK1800134T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK05809109T 2004-10-14 2005-10-13 Fremgangsmåde til diagnosticering og behandling af Chron's sygdom DK1800134T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0410865A FR2876798A1 (fr) 2004-10-14 2004-10-14 Diagnostic et traitement de la maladie de crohn
PCT/FR2005/002538 WO2006040481A2 (fr) 2004-10-14 2005-10-13 Procede de diagnostic et traitement de la maladie de crohn

Publications (1)

Publication Number Publication Date
DK1800134T3 true DK1800134T3 (da) 2009-03-16

Family

ID=34951162

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05809109T DK1800134T3 (da) 2004-10-14 2005-10-13 Fremgangsmåde til diagnosticering og behandling af Chron's sygdom

Country Status (10)

Country Link
US (2) US9176131B2 (de)
EP (1) EP1800134B1 (de)
JP (1) JP4896883B2 (de)
AT (1) ATE415632T1 (de)
CA (1) CA2582228C (de)
DE (1) DE602005011316D1 (de)
DK (1) DK1800134T3 (de)
ES (1) ES2317327T3 (de)
FR (1) FR2876798A1 (de)
WO (1) WO2006040481A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377883A1 (de) 2010-04-15 2011-10-19 Universite d'Auvergne Clermont I Antagonisten zur Vorbeugung oder Behandlung von entzündlicher Darmerkrankung, speziell von Morbus Crohn
ES2732311T3 (es) 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
CN104936969B (zh) 2012-12-18 2018-08-17 沃泰克斯药物股份有限公司 用于治疗细菌感染的甘露糖衍生物
JP6373352B2 (ja) 2013-03-12 2018-08-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 細菌感染を処置するためのマンノース誘導体
CN105682665A (zh) * 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法
CN104459154B (zh) * 2014-12-09 2016-04-27 临沂大学 一种新型人工模拟酶的合成及对糖基检测方法的构建
RU2018131440A (ru) 2016-03-23 2020-04-23 Фимбрион Терапеутикс, Инк. Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания
KR102373502B1 (ko) * 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
CN112334455B (zh) 2018-07-10 2022-07-01 葛兰素史密斯克莱知识产权发展有限公司 用于治疗尿路感染的c-甘露糖苷化合物
EP3757572A1 (de) * 2019-06-27 2020-12-30 Centre National de la Recherche Scientifique Nachweis von pathogenen bakterien durch chemisch funktionalisierte cellulose

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
JP3342749B2 (ja) * 1993-09-20 2002-11-11 積水化学工業株式会社 糖化蛋白の測定方法
EP0747705A1 (de) * 1995-06-09 1996-12-11 Bayer Corporation Spezifische Bestimmung von NCA 90 Glykoprotein im Blut eines Krebspatienten
WO1997018790A2 (en) * 1995-11-22 1997-05-29 The Research And Development Institute, Inc. Therapeutic and diagnostic agents for the treatment of microbial infections
US5874233A (en) 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US6290959B1 (en) * 1996-10-24 2001-09-18 New York University Method for screening compounds for inhibiting bacterial attachment to host cell receptors
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
WO2002086136A1 (en) * 2001-04-25 2002-10-31 N.V. Nutricia Process for the manufacture of a fermented health-promoting product
JP4947851B2 (ja) * 2001-06-07 2012-06-06 信紘 佐藤 潰瘍性大腸炎治療薬
AU2002313458A1 (en) * 2001-06-29 2003-03-03 Astion Development A/S Niaciamide and derivatives in combination with aminosugar
WO2003070266A1 (en) * 2001-10-12 2003-08-28 Mount Sinai School Of Medicine Enhanced immunization and suppression of oral tolerance
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
WO2005026318A2 (en) * 2003-07-31 2005-03-24 Endacea, Inc. Methods and compositions for producing antigenic responses
US7799328B2 (en) * 2004-12-23 2010-09-21 Biocodex Method for treating weight loss in patients suffering from inflammatory bowel diseases
US8476058B2 (en) * 2007-12-26 2013-07-02 Lesaffre Et Compagnie Probiotic yeast compositions and methods for inflammatory diseases

Also Published As

Publication number Publication date
JP4896883B2 (ja) 2012-03-14
ATE415632T1 (de) 2008-12-15
US20100015600A1 (en) 2010-01-21
US20160091501A1 (en) 2016-03-31
CA2582228C (fr) 2018-07-31
JP2008517261A (ja) 2008-05-22
WO2006040481A2 (fr) 2006-04-20
ES2317327T3 (es) 2009-04-16
WO2006040481A3 (fr) 2006-08-31
EP1800134A2 (de) 2007-06-27
DE602005011316D1 (de) 2009-01-08
US9176131B2 (en) 2015-11-03
EP1800134B1 (de) 2008-11-26
CA2582228A1 (fr) 2006-04-20
FR2876798A1 (fr) 2006-04-21

Similar Documents

Publication Publication Date Title
DK1800134T3 (da) Fremgangsmåde til diagnosticering og behandling af Chron's sygdom
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
DK1493439T3 (da) Middel til fastlæggelse af en persons risikoprofil for aterosklerotisk sygdom
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
MY154984A (en) Preventing autoimmune disease
DK1530724T3 (da) Diagnose og forebyggelse af cancercelleinvasion
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
PT1318837E (pt) Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
AU2003263603A8 (en) Method for diagnosing pancreatic cancer
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
HK1069767A1 (en) Methods for inhibiting ocular processes
WO2006066008A3 (en) Device and methods for identifying and treating aspirin non-responsive patients
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
WO2008118148A3 (en) Adiponectin for the treatment and diagnosis of albuminuria
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
DK1075277T4 (da) Fremgangsmåder til detektion og inhibering af angiogenese
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
SG163614A1 (en) Colon cancer related gene tom34
BRPI0409562A (pt) tratamento de condições envolvendo placas amilóides
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
WO2005089489A3 (en) Use of relaxin to increase arterial compliance
WO2006099569A3 (en) Methods and compositions for beryllium-induced disease
DE60024809D1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin